User fee-heavy budget proposes appears to tie into Trump's broader deregulatory strategy; CDER and CBER would have to make cuts to non-user fee safety initiatives.
While the US FDA would get a 10% bump in total resources to $5.1 billion for fiscal year (FY) 2018 under the Trump administration's proposed budget, the predominantly user fee-funded proposal would result in cuts to some of the agency's safety initiatives for its medical products and several non-user fee related programs.
The president's budget proposal, released May 23, would slash budgetary funding of the agency by $854 million, or roughly 31%...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
